caa a22 4500 469079584 CHVBK 20180323132946.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF00168946 doi (NATIONALLICENCE)springer-10.1007/BF00168946 Weak effects of local and systemic administration of the GABA uptake inhibitor, SK&F 89976, on extracellular GABA in the rat striatum [Elektronische Daten] [P.C. Waldmeier, K. Stöcklin, J.-J. Feldtrauer] Summary: The effects of local and systemic administration of the potent GABA uptake inhibitor, SK&F 89976, on GABA overflow from the striatum of conscious rats were investigated in brain dialysis experiments. Administration of the compound via the dialysis probe at concentrations of 25 or 100 μgmol/l significantly increased basal GABA overflow about 2-fold. Overflow evoked by 104 mmol/l K+ remained unaltered at the lower and was almost doubled at the higher concentration; this increase did, however, not reach statistical significance. Given systemically at 50 mg/kg i.p., a dose which is severalfold higher than those which exhibit anticonvulsant effects, SK&F 89976 caused a significant enhancement of K+-stimulated GABA overflow by about a factor of 2; the lower dose of 20 mg/kg i.p. was not effective. Basal GABA overflow was not significantly increased by either dose. These results suggest that the marked effects of nipecotic acid on basal GABA overflow reported by several authors seem to be related to GABA displacement rather than uptake inhibition, and that uptake inhibition does not improve the interpretability of measurements of GABA release by brain dialysis. They neither support the idea that the relative insensitivity of extracellular GABA to low Ca2+ and tetrodotoxin is indirectly due to very efficient removal of GABA by neuronal and/or glial uptake, leaving only residual amounts to be measured. Springer-Verlag, 1992 GABA uptake nationallicence K+ evoked GABA overflow nationallicence Brain dialysis nationallicence SK&F 89976 nationallicence Basal GABA overflow nationallicence Waldmeier P.C. Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Basel, Switzerland aut Stöcklin K. Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Basel, Switzerland aut Feldtrauer J.-J Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Basel, Switzerland aut Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 345/5(1992-05-01), 544-547 0028-1298 345:5<544 1992 345 210 https://doi.org/10.1007/BF00168946 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00168946 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Waldmeier P.C. Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Stöcklin K. Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Basel, Switzerland aut NATIONALLICENCE 700 1- Feldtrauer J.-J Research Department, Pharmaceuticals Division, Ciba-Geigy AG, Klybeckstrasse 141, CH-4002, Basel, Switzerland aut NATIONALLICENCE 773 0- Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 345/5(1992-05-01), 544-547 0028-1298 345:5<544 1992 345 210 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer